ArticleFrontiers in pediatrics2023
Impact of CytoSorb and CKRT on hemodynamics in pediatric patients with septic shock: the PedCyto study.
Article in Frontiers in pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05658588 (Impact of Cytosorb and CKRT on Hemodynamics in Pediatric Patients With Septic Shock), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Cytosorb and CKRT on Hemodynamics in Pediatric Patients With Septic Shock: the PedCyto Study
Who cites it
18 citing papers in PubMed, 17 citations in OpenAlex.
- Hemoadsorptionin Critically Ill Pediatric Oncology and Hemato-Oncology Patients: A Systematic Review with Structured Narrative Synthesis.Children (Basel, Switzerland) · 2026Review
- Novel extracorporeal therapies in children.Pediatric nephrology (Berlin, Germany) · 2026Article
- Exploratory dose modeling of hemoadsorption in pediatric septic shock.Intensive care medicine experimental · 2026Article
- Effects of hemoadsorption on plasma catecholamine levels: an in vitro study.Scientific reports · 2026Article
- Technicalities, current evidence, and clinical indications of hemoadsorption in critically ill children.Pediatric nephrology (Berlin, Germany) · 2026Review
- A review of systematic reviews on the CytoSorb® hemadsorption technology in sepsis and septic shock.Unfallchirurgie (Heidelberg, Germany) · 2026Article
- First experience of hemadsorption with HA60 cartridges in newborns and small infants with septic shock: a case series.Frontiers in pediatrics · 2026Article
- CytoSorb haemoadsorption in critically ill children: a multicentre observational study on feasibility, safety, and outcomes, the CYTOPED study.Annals of intensive care · 2026Article
- Hemoadsorbtion with Cytosorb in the Treatment of Refractory Cardiogenic Shock in a Septic Pediatric Patient: is it worth it?-Lessons for the clinical nephrologist.Journal of nephrology · 2025Article
- Continuous renal replacement therapy (CRRT) program initiation in PICU of a resource limited setting: a retrospective analysis of challenges and outcomes.BMC nephrology · 2025Article
- Immunomodulation in Pediatric Sepsis: A Narrative Review.Journal of clinical medicine · 2025Review
- Extracorporeal pediatric renal replacement therapy: diversifying application beyond kidney failure.Pediatric nephrology (Berlin, Germany) · 2025Review
- Hemoadsorption in the Management of Septic Shock: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Hemoadsorption in critically ill neonatal and pediatric patients: a retrospective cohort study from a Latin American tertiary center.Frontiers in medicine · 2025Article
- Endothelial Protection and Improved Micro- and Macrocirculation with Hemoadsorption in Critically Ill Patients.Journal of clinical medicine · 2024Review
- Hemoperfusion with CytoSorbJournal of clinical medicine · 2024Article
- The Sublingual Microcirculation in Critically Ill Children with Septic Shock Undergoing Hemoadsorption: A Pilot Study.Biomedicines · 2024Article
- Potential correlation between hemodynamic improvement and an immune-modulation effect in pediatric patients with septic shock treated with renal replacement therapy and CytoSorbCritical care (London, England) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is a lack of data to support the use of hemoadsorption in pediatric septic shock. The aim of our study was to assess the effectiveness and safety of CytoSorb therapy in this setting. Methods: Phase II interventional single arm pilot study in which 17 consecutive children admitted with septic shock who required continuous kidney replacement therapy (CKRT) and weighed ≥10 kg were included. A CytoSorb (CytoSorbents Inc, New Jersey, USA) hemoadsorption cartridge was added to the CKRT every 24 h for a maximum of 96 h. A control group of 13 children with septic shock treated with CKRT but not hemoadsorption at Children's Hospital Bambino Gesù and enrolled in the EuroAKId register was selected as an historical cohort. The primary outcome of the study was a reduction in vasopressor or inotrope dose of >50% from baseline by the end of CytoSorb therapy. Secondary outcomes included hemodynamic and biological changes, changes in severity scores, and 28-day mortality. Results: There were significant decreases in the Vasoactive Inotropic Score (VIS) and the Pediatric Logistic Organ Dysfunction 2 (PELOD-2) score at 72 and 96 h from the start of the CytoSorb therapy compared to baseline; the reductions were larger in the hemoadsorption group than in the control group (historical cohort). 28-day mortality was lower, although not significantly, in the hemoadsorption group when compared to the control group (5/17 [29%] vs. 8/13 [61%] OR 0.26 [95% CI: 0.05-1.2]; Conclusions: CytoSorb therapy may have some benefits in pediatric patients with septic shock Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT05658588, identifier (Clinicaltrials.gov NCT05658588).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.